Australia Pharmaceuticals & Healthcare Report

Published 24 April 2015

  • 145 pages
  • Instant access to your report online and PDF format through your account library
  • Includes 3 free updated quarterly reports
 
$1,295.00
Australia Pharmaceuticals & Healthcare Report

BMI View: The domestic backlash against the Australian government's budget saving efforts focusing on areas of the healthcare sector, including general practice copayments, will translate in to additional incentives for the government to place pressure on pharmaceutical expenditure. Patented drugs will continue to account for the majority of the pharmaceuticals market share in Australia, with this share to only slightly moderate over the next years. In fact, cost containment efforts will continue to present headwinds to multinational pharmaceutical companies seeking to list their products on the Australian Pharmaceutical Benefits Scheme and achieve premium price lev els. However, despite the challenging environment , we expect Australia's pharmaceuticals and healthcare sector to continue growing over the next few years.

Headline Expenditure Projections

  • Pharmaceuticals: AUD13.48bn (USD12.15bn) in 2014 to AUD14.06bn (USD10.68bn) in 2015; +4.3% in local currency terms and -12.1% in US dollar terms, due to significant exchange rate fluctuations. Forecast in line with last quarter.

  • Healthcare: AUD153.29bn (USD138.16bn) in 2014 to AUD160.01bn (USD121.61bn) in 2015; +4.4% in local currency terms and -12.0% in US dollar terms, due to exchange rate fluctuations. Forecast revised upwards from last quarter.

Risk/Rewards Index: In Q315 Australia is ranked as the third most attractive market in the Asia Pacific region (scoring 65.8 out of 100), after Japan (73.3) and South Korea (68.6). In Q315 we have revised downwards Australia's score from 67.0 in the last quarter on the back of lower industry rewards indices. Australia's score is driven by a relatively high drug spending per capita, a large pensionable population and robust population growth but dragged down by poor sector growth.

Key Trends And Developments

April 2015

  • Amneal Pharmaceuticals and Actavis Australia have signed a binding letter of intent under which Amneal will acquire...

Table of Contents

BMI Industry View
7
SWOT
9
Political
11
Economic
12
Operational Risk
13
Industry Forecast
14
Pharmaceutical Market Forecast
14
Table: Pharmaceutical Sales, Historical Data And Forecasts (Austria 2011-2019)
15
Healthcare Market Forecast
15
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Austria 2011-2019)
17
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Austria 2011-2019)
18
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Austria 2011-2019)
18
Prescription Drug Market Forecast
19
Table: Prescription Drug Market Indicators, Historical Data And Forecasts (Austria 2011-2019)
21
Patented Drug Market Forecast
21
Table: Patented Drug Market Indicators, Historical Data And Forecasts (Austria 2011-2019)
23
Generic Drug Market Forecast
24
Table: Generic Drug Market Indicators, Historical Data And Forecasts (Austria 2011-2019)
26
OTC Medicine Market Forecast
26
Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (Austria 2011-2019)
28
Pharmaceutical Trade Forecast
28
Table: Pharmaceutical Trade Data And Forecasts (Austria 2013-2019)
29
Table: Pharmaceutical Trade Data And Forecasts local currency (Austria 2013-2019)
30
Key Risks To BMI's Forecast
30
Macroeconomic Forecasts
31
Economic Analysis
31
Table: Economic Activity (Austria 2010-2019)
35
Industry Risk Reward Ratings
36
Western Europe Risk/Reward Index
36
Austria Risk/Reward Index
40
Rewards
40
Risks
41
Market Overview
43
Industry Trends And Developments
45
Epidemiology
45
Healthcare Sector
46
Table: Healthcare Resources (Austria 2009-2014)
48
Table: Healthcare Personnel (Austria 2009-2014)
48
Table: Healthcare Activity (Austria 2009-2014)
49
Research & Development
49
Clinical Trials
50
Regulatory Development
51
Intellectual Property Issues
53
Competitive Landscape
56
Research-Based Industry
56
Pharmaceutical Distribution
58
Table: Members Of ARGE Pharmazeutika, 2011
59
Pharmaceutical Retail
61
Table: Pharmacy Outlets by Type, 2005-2009
62
Table: Pharmacy Outlets by State, 2005-2009
62
Demographic Forecast
63
Table: Population Headline Indicators (Austria 1990-2025)
64
Table: Key Population Ratios (Austria 1990-2025)
64
Table: Urban/Rural Population & Life Expectancy (Austria 1990-2025)
65
Table: Population By Age Group (Austria 1990-2025)
65
Table: Population By Age Group % (Austria 1990-2025)
66
Glossary
68
Methodology
70
Pharmaceutical Expenditure Forecast Model
70
Healthcare Expenditure Forecast Model
70
Notes On Methodology
71
Risk/Reward Index Methodology
72
Index Overview
73
Table: Pharmaceutical Risk/Reward Index Indicators
73
Indicator Weightings
74

The Australia Pharmaceuticals & Healthcare Report features BMI Research's forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.

BMI's Australia Pharmaceuticals & Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the Australia pharmaceutical and healthcare industry.

Key Benefits

  • Benchmark BMI's pharmaceutical and healthcare market forecasts for Australia, to test other views - a key input for successful budgeting and strategic business planning in the Australian pharmaceutical and healthcare market.
  • Target business opportunities and risks in the Australian pharmaceutical and healthcare sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in Australia.
  • Assess the activities, strategy and market position of your competitors using our company profiles (including SWOTs, KPIs and latest activity) and competitive landscape tables.

Coverage

BMI Industry View

An at-a-glance perspective on the latest regulatory developments, key forecast indicators and major corporate developments, covering the prescription, OTC and generics markets. The pharmaceuticals and healthcare SWOT outlines strategic factors that affect the basic assumptions underpinning BMI’s forecast analysis, and taken together with BMI’s political, economic and business environment SWOTs, it gives a complete overview of market climate.

BMI Industry Forecast Scenario

Industry forecasts to end-2019 for all key indicators, supported by explicit assumptions, plus analysis of key downside risks to the main forecasts:

  • Healthcare: Total healthcare expenditure (USDbn), healthcare expenditure (% of GDP), healthcare expenditure per capita (USD), hospital beds, doctors, and birth & mortality rates (all per ‘000 population).
  • Pharmaceutical Market: Drug expenditure in USDbn, % of GDP and per capita (USD).
  • Patented Drug Market: Prescription drug sales (USDbn & % of total sales).
  • Generic Drug Market: Generic product sales (USDbn), generic sales (% of total sales).
  • OTC Drug Market: OTC sales (USDbn & % of total sales).
  • Macroeconomic Forecasts: Nominal and real GDP, % real GDP growth, % private consumption growth, % industrial output growth, % consumer price index, % GDP price deflator, exports, imports, trade balance, current account balance, foreign direct investment, exchange rate against USD, government expenditure and external debt.

BMI’s Pharmaceuticals and Healthcare Risk Reward Index

BMI’s Risk Reward Index provides investors (both national and multinational) looking for opportunities in the region with a clear country-comparative assessment of the market’s risks and potential rewards. Each of the country markets are scored using a sophisticated model that includes more than 40 industry, economic and demographic data points to provide indices of highest to lowest appeal to investors, with each position explained.

Market Summary

A snapshot of key market characteristics, including total size of the pharmaceuticals and healthcare segments, growth drivers, leading therapeutic areas and the competitive landscape

Industry Developments

A focus on government healthcare reforms, epidemiological trends, mergers and acquisitions, product launches, market entries, FDI activity, R&D, biotechnology, clinical trials and supply chain issues.

Regulatory Regime

Details of the industry regulatory framework and key legislation covering the licensing of new products/services, pricing and reimbursements, intellectual property, taxation and advertising, as well as analysis of the overall regulatory burden.

Competitive Landscape

The competitive landscape section provides comparative company analyses and index by USD sales and % share of total sales – for the total pharmaceutical sector, as well as the OTC, generics and distribution sub-sectors.

Company Profiles*

Examines the competitive positioning and short- to medium-term business strategies of key industry players. Strategy is examined within the context of BMI’s industry forecasts, our macroeconomic views and our understanding of the wider competitive landscape to generate Company SWOT analyses. The latest financial and operating statistics and key company developments are also incorporated within the company profiles, enabling a full evaluation of recent company performance and future growth prospects.

*Company profiles are not available for every country. Those reports instead contain information on the current activities of prominent companies operating in the market.

secure
Benefit from discounts when you add multiple products to your basket
2 Products SAVE 10%
3 Products SAVE 15%
4 Products SAVE 20%
5 Products SAVE 25%
6 Products SAVE 30%
7 - 20 Products SAVE 35%
21 Products or more SAVE 40%

Testimonials

'An essential, multi-faceted research tool. BMI’s thorough understanding of the major market players enables an informed – and informative – review of the sector’s actual performance, together with useful insights into current industry issues, which are topped-off with detailed and invaluable forecasts of industry and macroeconomic trends.’

Senior Research Analyst, ABC International Bank plc